Small molecule adenosine 5′-monophosphate activated protein kinase (AMPK) modulators and human diseases

Journal of Medicinal Chemistry

Volumn 58, Issue 1, 2015, Pages 2-29

  Rana, Sandeep ^a   Blowers, Elizabeth C ^a   Natarajan, Amarnath ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ADENINE NUCLEOTIDE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; ARSENIC TRIOXIDE; BENZIMIDAZOLE DERIVATIVE; BERBERINE; BIPHENYL DERIVATIVE; CURCUMIN; EPIGALLOCATECHIN GALLATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; INSULIN; METFORMIN; NICOTINAMIDE DERIVATIVE; PIOGLITAZONE; PYRIDONE DERIVATIVE; QUERCETIN; R 419; RAPAMYCIN; RESVERATROL; ROSIGLITAZONE; SALICYLIC ACID; SANGUINARINE; SYNTHETIC PEPTIDE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; MOLECULAR LIBRARY; PROTEIN KINASE MODULATOR; SIGNAL PEPTIDE;

ALZHEIMER DISEASE; ARTICLE; BINDING SITE; CANCER PATIENT; CATALYSIS; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; FATTY ACID OXIDATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; LIPID METABOLISM; LIPOGENESIS; MEDIATOR; METABOLIC DISORDER; METABOLISM; NEOPLASM; NONHUMAN; PHENOTYPE; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ALLOSTERISM; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLIC DISEASES; MOLECULAR LIBRARY; NEOPLASMS; PHARMACOLOGY; PROTEIN TERTIARY STRUCTURE;

ADENINE NUCLEOTIDES; ALLOSTERIC REGULATION; AMP-ACTIVATED PROTEIN KINASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; METABOLIC DISEASES; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; SMALL MOLECULE LIBRARIES;

EID: 84920982798     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401994c     Document Type: Article

References (274)

1. Hardie, D. G.; Ross, F. A.; Hawley, S. A. AMP-activated protein kinase: a target for drugs both ancient and modern Chem. Biol. 2012, 19, 1222-1236
2. Carling, D.; Clarke, P. R.; Zammit, V. A.; Hardie, D. G. Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities Eur. J. Biochem. 1989, 186, 129-136
3. Carling, D.; Hardie, D. G. The substrate and sequence specificity of the AMP-activated protein kinase. Phosphorylation of glycogen synthase and phosphorylase kinase Biochim. Biophys. Acta 1989, 1012, 81-86
4. Browne, G. J.; Finn, S. G.; Proud, C. G. Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398 J. Biol. Chem. 2004, 279, 12220-12231
5. Davies, S. P.; Sim, A. T.; Hardie, D. G. Location and function of three sites phosphorylated on rat acetyl-CoA carboxylase by the AMP-activated protein kinase Eur. J. Biochem. 1990, 187, 183-190
6. Davies, S. P.; Carling, D.; Hardie, D. G. Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay Eur. J. Biochem. 1989, 186, 123-128
7. Winder, W. W.; Wilson, H. A.; Hardie, D. G.; Rasmussen, B. B.; Hutber, C. A.; Call, G. B.; Clayton, R. D.; Conley, L. M.; Yoon, S.; Zhou, B. Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A J. Appl. Physiol. 1997, 82) 219-225
8. Inoue, E.; Yamauchi, J. AMP-activated protein kinase regulates PEPCK gene expression by direct phosphorylation of a novel zinc finger transcription factor Biochem. Biophys. Res. Commun. 2006, 351, 793-799
9. Treebak, J. T.; Glund, S.; Deshmukh, A.; Klein, D. K.; Long, Y. C.; Jensen, T. E.; Jorgensen, S. B.; Viollet, B.; Andersson, L.; Neumann, D.; Wallimann, T.; Richter, E. A.; Chibalin, A. V.; Zierath, J. R.; Wojtaszewski, J. F. AMPK-mediated AS160 phosphorylation in skeletal muscle is dependent on AMPK catalytic and regulatory subunits Diabetes 2006, 55, 2051-2058
10. Chen, Z. P.; Mitchelhill, K. I.; Michell, B. J.; Stapleton, D.; Rodriguez-Crespo, I.; Witters, L. A.; Power, D. A.; Ortiz de Montellano, P. R.; Kemp, B. E. AMP-activated protein kinase phosphorylation of endothelial NO synthase FEBS Lett. 1999, 443, 285-289
11. Holmes, B. F.; Sparling, D. P.; Olson, A. L.; Winder, W. W.; Dohm, G. L. Regulation of muscle GLUT4 enhancer factor and myocyte enhancer factor 2 by AMP-activated protein kinase Am. J. Physiol.: Endocrinol. Metab. 2005, 289, E1071-E1076
12. Hong, Y. H.; Varanasi, U. S.; Yang, W.; Leff, T. AMP-activated protein kinase regulates HNF4alpha transcriptional activity by inhibiting dimer formation and decreasing protein stability J. Biol. Chem. 2003, 278, 27495-27501
13. Jakobsen, S. N.; Hardie, D. G.; Morrice, N.; Tornqvist, H. E. 5′-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside J. Biol. Chem. 2001, 276, 46912-46916
14. Chen, Z. P.; McConell, G. K.; Michell, B. J.; Snow, R. J.; Canny, B. J.; Kemp, B. E. AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation Am. J. Physiol.: Endocrinol. Metab. 2000, 279, E1202-E1206
15. Liang, J.; Shao, S. H.; Xu, Z. X.; Hennessy, B.; Ding, Z.; Larrea, M.; Kondo, S.; Dumont, D. J.; Gutterman, J. U.; Walker, C. L.; Slingerland, J. M.; Mills, G. B. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis Nat. Cell Biol. 2007, 9, 218-224
16. Yang, W.; Hong, Y. H.; Shen, X. Q.; Frankowski, C.; Camp, H. S.; Leff, T. Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors J. Biol. Chem. 2001, 276, 38341-38344
17. Marsin, A. S.; Bertrand, L.; Rider, M. H.; Deprez, J.; Beauloye, C.; Vincent, M. F.; Van den Berghe, G.; Carling, D.; Hue, L. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia Curr. Biol. 2000, 10, 1247-1255
18. Inoki, K.; Zhu, T.; Guan, K. L. TSC2 mediates cellular energy response to control cell growth and survival Cell 2003, 115, 577-590
19. Banko, M. R.; Allen, J. J.; Schaffer, B. E.; Wilker, E. W.; Tsou, P.; White, J. L.; Villen, J.; Wang, B.; Kim, S. R.; Sakamoto, K.; Gygi, S. P.; Cantley, L. C.; Yaffe, M. B.; Shokat, K. M.; Brunet, A. Chemical genetic screen for AMPKalpha2 substrates uncovers a network of proteins involved in mitosis Mol. Cell 2011, 44, 878-892
20. Shaw, L. M.; Vanderstichele, H.; Knapik-Czajka, M.; Clark, C. M.; Aisen, P. S.; Petersen, R. C.; Blennow, K.; Soares, H.; Simon, A.; Lewczuk, P.; Dean, R.; Siemers, E.; Potter, W.; Lee, V. M.; Trojanowski, J. Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann. Neurol. 2009, 65, 403-413
21. Won, J. S.; Im, Y. B.; Kim, J.; Singh, A. K.; Singh, I. Involvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesis Biochem. Biophys. Res. Commun. 2010, 399, 487-491
22. Hawley, S. A.; Davison, M.; Woods, A.; Davies, S. P.; Beri, R. K.; Carling, D.; Hardie, D. G. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase J. Biol. Chem. 1996, 271, 27879-27887
23. Shaw, R. J.; Kosmatka, M.; Bardeesy, N.; Hurley, R. L.; Witters, L. A.; DePinho, R. A.; Cantley, L. C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 3329-3335
24. Woods, A.; Johnstone, S. R.; Dickerson, K.; Leiper, F. C.; Fryer, L. G.; Neumann, D.; Schlattner, U.; Wallimann, T.; Carlson, M.; Carling, D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade Curr. Biol. 2003, 13, 2004-2008
25. Hawley, S. A.; Pan, D. A.; Mustard, K. J.; Ross, L.; Bain, J.; Edelman, A. M.; Frenguelli, B. G.; Hardie, D. G. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase Cell Metab. 2005, 2, 9-19
26. Woods, A.; Dickerson, K.; Heath, R.; Hong, S. P.; Momcilovic, M.; Johnstone, S. R.; Carlson, M.; Carling, D. Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells Cell Metab. 2005, 2, 21-33
27. Momcilovic, M.; Hong, S. P.; Carlson, M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro J. Biol. Chem. 2006, 281, 25336-25343
28. Suter, M.; Riek, U.; Tuerk, R.; Schlattner, U.; Wallimann, T.; Neumann, D. Dissecting the role of 5′-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase J. Biol. Chem. 2006, 281, 32207-32216
29. Davies, S. P.; Helps, N. R.; Cohen, P. T.; Hardie, D. G. 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC FEBS Lett. 1995, 377, 421-425
30. Voss, M.; Paterson, J.; Kelsall, I. R.; Martin-Granados, C.; Hastie, C. J.; Peggie, M. W.; Cohen, P. T. Ppm1E is an in cellulo AMP-activated protein kinase phosphatase Cell. Signalling 2011, 23, 114-124
31. Chen, L.; Jiao, Z. H.; Zheng, L. S.; Zhang, Y. Y.; Xie, S. T.; Wang, Z. X.; Wu, J. W. Structural insight into the autoinhibition mechanism of AMP-activated protein kinase Nature 2009, 459, 1146-1149
32. Oakhill, J. S.; Chen, Z. P.; Scott, J. W.; Steel, R.; Castelli, L. A.; Ling, N.; Macaulay, S. L.; Kemp, B. E. beta-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK) Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 19237-19241
33. McBride, A.; Ghilagaber, S.; Nikolaev, A.; Hardie, D. G. The glycogen-binding domain on the AMPK beta subunit allows the kinase to act as a glycogen sensor Cell Metab. 2009, 9, 23-34
34. Xiao, B.; Heath, R.; Saiu, P.; Leiper, F. C.; Leone, P.; Jing, C.; Walker, P. A.; Haire, L.; Eccleston, J. F.; Davis, C. T.; Martin, S. R.; Carling, D.; Gamblin, S. J. Structural basis for AMP binding to mammalian AMP-activated protein kinase Nature 2007, 449, 496-500
35. Kemp, B. E.; Oakhill, J. S.; Scott, J. W. AMPK structure and regulation from three angles Structure 2007, 15, 1161-1163
36. Xiao, B.; Sanders, M. J.; Underwood, E.; Heath, R.; Mayer, F. V.; Carmena, D.; Jing, C.; Walker, P. A.; Eccleston, J. F.; Haire, L. F.; Saiu, P.; Howell, S. A.; Aasland, R.; Martin, S. R.; Carling, D.; Gamblin, S. J. Structure of mammalian AMPK and its regulation by ADP Nature 2011, 472, 230-233
37. Xiao, B.; Sanders, M. J.; Carmena, D.; Bright, N. J.; Haire, L. F.; Underwood, E.; Patel, B. R.; Heath, R. B.; Walker, P. A.; Hallen, S.; Giordanetto, F.; Martin, S. R.; Carling, D.; Gamblin, S. J. Structural basis of AMPK regulation by small molecule activators Nat. Commun. 2013, 4, 3017
38. Kumar, E. A.; Chen, Q.; Kizhake, S.; Kolar, C.; Kang, M.; Chang, C. E.; Borgstahl, G. E.; Natarajan, A. The paradox of conformational constraint in the design of Cbl(TKB)-binding peptides Sci. Rep. 2013, 3, 1639
39. Pessetto, Z. Y.; Yan, Y.; Bessho, T.; Natarajan, A. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option Breast Cancer Res. Treat. 2012, 134, 511-517
40. Kumar, E. A.; Yuan, Z.; Palermo, N. Y.; Dong, L.; Ahmad, G.; Lokesh, G. L.; Kolar, C.; Kizhake, S.; Borgstahl, G. E.; Band, H.; Natarajan, A. Peptide truncation leads to a twist and an unusual increase in affinity for casitas B-lineage lymphoma tyrosine kinase binding domain J. Med. Chem. 2012, 55, 3583-3587
41. Yuan, Z.; Kumar, E. A.; Kizhake, S.; Natarajan, A. Structure-activity relationship studies to probe the phosphoprotein binding site on the carboxy terminal domains of the breast cancer susceptibility gene 1 J. Med. Chem. 2011, 54, 4264-4268
42. Yuan, Z.; Kumar, E. A.; Campbell, S. J.; Palermo, N. Y.; Kizhake, S.; Mark Glover, J. N.; Natarajan, A. Exploiting the P-1 pocket of BRCT domains toward a structure guided inhibitor design ACS Med. Chem. Lett. 2011, 2, 764-767
43. Kumar, E. A.; Charvet, C. D.; Lokesh, G. L.; Natarajan, A. High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-protein tyrosine kinase interactions Anal. Biochem. 2011, 411, 254-260
44. Anisimov, V. M.; Ziemys, A.; Kizhake, S.; Yuan, Z.; Natarajan, A.; Cavasotto, C. N. Computational and experimental studies of the interaction between phospho-peptides and the C-terminal domain of BRCA1 J. Comput.-Aided Mol. Des 2011, 25, 1071-1084
45. Joseph, P. R.; Yuan, Z.; Kumar, E. A.; Lokesh, G. L.; Kizhake, S.; Rajarathnam, K.; Natarajan, A. Structural characterization of BRCT-tetrapeptide binding interactions Biochem. Biophys. Res. Commun. 2010, 393, 207-210
46. Simeonov, A.; Yasgar, A.; Jadhav, A.; Lokesh, G. L.; Klumpp, C.; Michael, S.; Austin, C. P.; Natarajan, A.; Inglese, J. Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction Anal. Biochem. 2008, 375, 60-70
47. Lokesh, G. L.; Muralidhara, B. K.; Negi, S. S.; Natarajan, A. Thermodynamics of phosphopeptide tethering to BRCT: the structural minima for inhibitor design J. Am. Chem. Soc. 2007, 129, 10658-10659
48. Lokesh, G. L.; Rachamallu, A.; Kumar, G. D.; Natarajan, A. High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1 Anal. Biochem. 2006, 352, 135-141
49. Hawley, S. A.; Selbert, M. A.; Goldstein, E. G.; Edelman, A. M.; Carling, D.; Hardie, D. G. 5′-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms J. Biol. Chem. 1995, 270, 27186-27191
50. Hardie, D. G. Sensing of energy and nutrients by AMP-activated protein kinase Am. J. Clin. Nutr. 2011, 93, 891S-896S
51. Grisouard, J.; Timper, K.; Radimerski, T. M.; Frey, D. M.; Peterli, R.; Kola, B.; Korbonits, M.; Herrmann, P.; Krahenbuhl, S.; Zulewski, H.; Keller, U.; Muller, B.; Christ-Crain, M. Mechanisms of metformin action on glucose transport and metabolism in human adipocytes Biochem. Pharmacol. 2010, 80, 1736-1745
52. Ong, K. W.; Hsu, A.; Tan, B. K. Chlorogenic acid stimulates glucose transport in skeletal muscle via AMPK activation: a contributor to the beneficial effects of coffee on diabetes PLoS One 2012, 7, e32718
53. Weisova, P.; Concannon, C. G.; Devocelle, M.; Prehn, J. H.; Ward, M. W. Regulation of glucose transporter 3 surface expression by the AMP-activated protein kinase mediates tolerance to glutamate excitation in neurons J. Neurosci. 2009, 29, 2997-3008
54. Marsin, A. S.; Bouzin, C.; Bertrand, L.; Hue, L. The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase J. Biol. Chem. 2002, 277, 30778-30783
55. Bultot, L.; Guigas, B.; Von Wilamowitz-Moellendorff, A.; Maisin, L.; Vertommen, D.; Hussain, N.; Beullens, M.; Guinovart, J. J.; Foretz, M.; Viollet, B.; Sakamoto, K.; Hue, L.; Rider, M. H. AMP-activated protein kinase phosphorylates and inactivates liver glycogen synthase Biochem. J. 2012, 443, 193-203
56. Scott, J. W.; Norman, D. G.; Hawley, S. A.; Kontogiannis, L.; Hardie, D. G. Protein kinase substrate recognition studied using the recombinant catalytic domain of AMP-activated protein kinase and a model substrate J. Mol. Biol. 2002, 317, 309-323
57. Hardie, D. G. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function Genes Dev. 2011, 25, 1895-1908
58. Holmes, B. F.; Sparling, D. P.; Olson, A. L.; Winder, W. W.; Dohm, G. L. Regulation of muscle GLUT4 enhancer factor and myocyte enhancer factor 2 by AMP-activated protein kinase Am. J. Physiol.: Endocrinol. Metab. 2005, 289, E1071-E1076
59. Oliveira, S. M.; Zhang, Y. H.; Solis, R. S.; Isackson, H.; Bellahcene, M.; Yavari, A.; Pinter, K.; Davies, J. K.; Ge, Y.; Ashrafian, H.; Walker, J. W.; Carling, D.; Watkins, H.; Casadei, B.; Redwood, C. AMP-activated protein kinase phosphorylates cardiac troponin I and alters contractility of murine ventricular myocytes Circ. Res. 2012, 110, 1192-1201
60. Liu, Y.; Lai, Y. C.; Hill, E. V.; Tyteca, D.; Carpentier, S.; Ingvaldsen, A.; Vertommen, D.; Lantier, L.; Foretz, M.; Dequiedt, F.; Courtoy, P. J.; Erneux, C.; Viollet, B.; Shepherd, P. R.; Tavare, J. M.; Jensen, J.; Rider, M. H. Phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is an AMPK target participating in contraction-stimulated glucose uptake in skeletal muscle Biochem. J. 2013, 455, 195-206
61. She, P.; Shiota, M.; Shelton, K. D.; Chalkley, R.; Postic, C.; Magnuson, M. A. Phosphoenolpyruvate carboxykinase is necessary for the integration of hepatic energy metabolism Mol. Cell. Biol. 2000, 20, 6508-6517
62. Lochhead, P. A.; Salt, I. P.; Walker, K. S.; Hardie, D. G.; Sutherland, C. 5-Aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase Diabetes 2000, 49, 896-903
63. Yamauchi, T.; Kamon, J.; Minokoshi, Y.; Ito, Y.; Waki, H.; Uchida, S.; Yamashita, S.; Noda, M.; Kita, S.; Ueki, K.; Eto, K.; Akanuma, Y.; Froguel, P.; Foufelle, F.; Ferre, P.; Carling, D.; Kimura, S.; Nagai, R.; Kahn, B. B.; Kadowaki, T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase Nat. Med. 2002, 8, 1288-1295
64. Yuan, L.; Ziegler, R.; Hamann, A. Inhibition of phosphoenolpyruvate carboxykinase gene expression by metformin in cultured hepatocytes Chin. Med. J. (Beijing, China, Engl. Ed.) 2002, 115, 1843-1848
65. Reid, M. B. Role of nitric oxide in skeletal muscle: synthesis, distribution and functional importance Acta Physiol. Scand. 1998, 162, 401-409
66. Shoelson, S. E.; Chatterjee, S.; Chaudhuri, M.; White, M. F. YMXM motifs of IRS-1 define substrate specificity of the insulin receptor kinase Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 2027-2031
67. Yenush, L.; White, M. F. The IRS-signalling system during insulin and cytokine action BioEssays 1997, 19, 491-500
68. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M. F.; Goodyear, L. J.; Moller, D. E. Role of AMP-activated protein kinase in mechanism of metformin action J. Clin. Invest. 2001, 108, 1167-1174
69. Chopra, I.; Li, H. F.; Wang, H.; Webster, K. A. Phosphorylation of the insulin receptor by AMP-activated protein kinase (AMPK) promotes ligand-independent activation of the insulin signalling pathway in rodent muscle Diabetologia 2012, 55, 783-794
70. Wang, F.; Marshall, C. B.; Ikura, M. Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition Cell. Mol. Life Sci. 2013, 70, 3989-4008
71. Ikonomov, O. C.; Sbrissa, D.; Dondapati, R.; Shisheva, A. ArPIKfyve-PIKfyve interaction and role in insulin-regulated GLUT4 translocation and glucose transport in 3T3-L1 adipocytes Exp. Cell Res. 2007, 313, 2404-2416
72. Dossus, L.; Kaaks, R. Nutrition, metabolic factors and cancer risk Best Pract. Res., Clin. Endocrinol. Metab. 2008, 22, 551-571
73. Hawley, S. A.; Boudeau, J.; Reid, J. L.; Mustard, K. J.; Udd, L.; Makela, T. P.; Alessi, D. R.; Hardie, D. G. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade J. Biol. 2003, 2, 28
74. Hemminki, A. The molecular basis and clinical aspects of Peutz-Jeghers syndrome Cell. Mol. Life Sci. 1999, 55, 735-750
75. Buzzai, M.; Jones, R. G.; Amaravadi, R. K.; Lum, J. J.; DeBerardinis, R. J.; Zhao, F.; Viollet, B.; Thompson, C. B. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth Cancer Res. 2007, 67, 6745-6752
76. Shaw, R. J.; Bardeesy, N.; Manning, B. D.; Lopez, L.; Kosmatka, M.; DePinho, R. A.; Cantley, L. C. The LKB1 tumor suppressor negatively regulates mTOR signaling Cancer Cell 2004, 6, 91-99
77. Shaw, R. J. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth Acta Physiol. 2009, 196, 65-80
78. Shamji, A. F.; Nghiem, P.; Schreiber, S. L. Integration of growth factor and nutrient signaling: implications for cancer biology Mol. Cell 2003, 12, 271-280
79. Tiainen, M.; Vaahtomeri, K.; Ylikorkala, A.; Makela, T. P. Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1) Hum. Mol. Genet. 2002, 11, 1497-1504
80. Jones, R. G.; Plas, D. R.; Kubek, S.; Buzzai, M.; Mu, J.; Xu, Y.; Birnbaum, M. J.; Thompson, C. B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint Mol. Cell 2005, 18, 283-293
81. Gwinn, D. M.; Shackelford, D. B.; Egan, D. F.; Mihaylova, M. M.; Mery, A.; Vasquez, D. S.; Turk, B. E.; Shaw, R. J. AMPK phosphorylation of raptor mediates a metabolic checkpoint Mol. Cell 2008, 30, 214-226
82. Kwiatkowski, D. J.; Zhang, H.; Bandura, J. L.; Heiberger, K. M.; Glogauer, M.; el-Hashemite, N.; Onda, H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells Hum. Mol. Genet. 2002, 11, 525-534
83. Zhang, H.; Cicchetti, G.; Onda, H.; Koon, H. B.; Asrican, K.; Bajraszewski, N.; Vazquez, F.; Carpenter, C. L.; Kwiatkowski, D. J. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR J. Clin. Invest. 2003, 112, 1223-1233
84. Stambolic, V.; Suzuki, A.; de la Pompa, J. L.; Brothers, G. M.; Mirtsos, C.; Sasaki, T.; Ruland, J.; Penninger, J. M.; Siderovski, D. P.; Mak, T. W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN Cell 1998, 95, 29-39
85. Ramaswamy, S.; Nakamura, N.; Vazquez, F.; Batt, D. B.; Perera, S.; Roberts, T. M.; Sellers, W. R. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 2110-2115
86. Warburg, O. On the origin of cancer cells Science 1956, 123, 309-314
87. Kim, J. W.; Dang, C. V. Cancer's molecular sweet tooth and the Warburg effect Cancer Res. 2006, 66, 8927-8930
88. Faubert, B.; Boily, G.; Izreig, S.; Griss, T.; Samborska, B.; Dong, Z.; Dupuy, F.; Chambers, C.; Fuerth, B. J.; Viollet, B.; Mamer, O. A.; Avizonis, D.; DeBerardinis, R. J.; Siegel, P. M.; Jones, R. G. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo Cell Metab. 2013, 17, 113-124
89. Adams, J. M.; Harris, A. W.; Pinkert, C. A.; Corcoran, L. M.; Alexander, W. S.; Cory, S.; Palmiter, R. D.; Brinster, R. L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice Nature 1985, 318, 533-538
90. Hoyer-Hansen, M.; Jaattela, M. AMP-activated protein kinase: a universal regulator of autophagy? Autophagy 2007, 3, 381-383
91. Hippert, M. M.; O'Toole, P. S.; Thorburn, A. Autophagy in cancer: good, bad, or both? Cancer Res. 2006, 66, 9349-9351
92. Park, H. U.; Suy, S.; Danner, M.; Dailey, V.; Zhang, Y.; Li, H.; Hyduke, D. R.; Collins, B. T.; Gagnon, G.; Kallakury, B.; Kumar, D.; Brown, M. L.; Fornace, A.; Dritschilo, A.; Collins, S. P. AMP-activated protein kinase promotes human prostate cancer cell growth and survival Mol. Cancer Ther. 2009, 8, 733-741
93. Liang, J.; Mills, G. B. AMPK: a contextual oncogene or tumor suppressor? Cancer Res. 2013, 73, 2929-2935
94. Jeon, S. M.; Hay, N. The dark face of AMPK as an essential tumor promoter Cell. Logistics 2012, 2, 197-202
95. Jeon, S. M.; Chandel, N. S.; Hay, N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress Nature 2012, 485, 661-665
96. Villena, J. A.; Viollet, B.; Andreelli, F.; Kahn, A.; Vaulont, S.; Sul, H. S. Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit Diabetes 2004, 53, 2242-2249
97. Hardie, D. G. AMPK: a target for drugs and natural products with effects on both diabetes and cancer Diabetes 2013, 62, 2164-2172
98. Jenkins, Y.; Sun, T. Q.; Markovtsov, V.; Foretz, M.; Li, W.; Nguyen, H.; Li, Y.; Pan, A.; Uy, G.; Gross, L.; Baltgalvis, K.; Yung, S. L.; Gururaja, T.; Kinoshita, T.; Owyang, A.; Smith, I. J.; McCaughey, K.; White, K.; Godinez, G.; Alcantara, R.; Choy, C.; Ren, H.; Basile, R.; Sweeny, D. J.; Xu, X.; Issakani, S. D.; Carroll, D. C.; Goff, D. A.; Shaw, S. J.; Singh, R.; Boros, L. G.; Laplante, M. A.; Marcotte, B.; Kohen, R.; Viollet, B.; Marette, A.; Payan, D. G.; Kinsella, T. M.; Hitoshi, Y. AMPK activation through mitochondrial regulation results in increased substrate oxidation and improved metabolic parameters in models of diabetes PLoS One 2013, 8, e81870
99. Baltgalvis, K. A.; White, K.; Li, W.; Claypool, M. D.; Lang, W.; Alcantara, R.; Singh, B. K.; Friera, A. M.; McLaughlin, J.; Hansen, D.; McCaughey, K.; Nguyen, H.; Smith, I. J.; Godinez, G.; Shaw, S. J.; Goff, D.; Singh, R.; Markovtsov, V.; Sun, T. Q.; Jenkins, Y.; Uy, G.; Li, Y.; Pan, A.; Gururaja, T.; Lau, D.; Park, G.; Hitoshi, Y.; Payan, D. G.; Kinsella, T. M. Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice Am. J. Physiol.: Heart Circ. Physiol. 2014, 306, H1128-1145
100. Okada-Iwabu, M.; Yamauchi, T.; Iwabu, M.; Honma, T.; Hamagami, K.; Matsuda, K.; Yamaguchi, M.; Tanabe, H.; Kimura-Someya, T.; Shirouzu, M.; Ogata, H.; Tokuyama, K.; Ueki, K.; Nagano, T.; Tanaka, A.; Yokoyama, S.; Kadowaki, T. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity Nature 2013, 503, 493-499
101. Menendez, J. A.; Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis Nat. Rev. Cancer 2007, 7, 763-777
102. Swinnen, J. V.; Beckers, A.; Brusselmans, K.; Organe, S.; Segers, J.; Timmermans, L.; Vanderhoydonc, F.; Deboel, L.; Derua, R.; Waelkens, E.; De Schrijver, E.; Van de Sande, T.; Noel, A.; Foufelle, F.; Verhoeven, G. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype Cancer Res. 2005, 65, 2441-2448
103. Scaglia, N.; Tyekucheva, S.; Zadra, G.; Photopoulos, C.; Loda, M. De novo fatty acid synthesis at the mitotic exit is required to complete cellular division Cell Cycle 2014, 13, 859-868
104. Zadra, G.; Photopoulos, C.; Tyekucheva, S.; Heidari, P.; Weng, Q. P.; Fedele, G.; Liu, H.; Scaglia, N.; Priolo, C.; Sicinska, E.; Mahmood, U.; Signoretti, S.; Birnberg, N.; Loda, M. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis EMBO Mol. Med. 2014, 6, 519-538
105. Vazquez-Martin, A.; Oliveras-Ferraros, C.; Lopez-Bonet, E.; Menendez, J. A. AMPK: evidence for an energy-sensing cytokinetic tumor suppressor Cell Cycle 2009, 8, 3679-3683
106. Gauthier, M. S.; O'Brien, E. L.; Bigornia, S.; Mott, M.; Cacicedo, J. M.; Xu, X. J.; Gokce, N.; Apovian, C.; Ruderman, N. Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans Biochem. Biophys. Res. Commun. 2011, 404, 382-387
107. Yu, X.; McCorkle, S.; Wang, M.; Lee, Y.; Li, J.; Saha, A. K.; Unger, R. H.; Ruderman, N. B. Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition Diabetologia 2004, 47, 2012-2021
108. Kelly, M.; Keller, C.; Avilucea, P. R.; Keller, P.; Luo, Z.; Xiang, X.; Giralt, M.; Hidalgo, J.; Saha, A. K.; Pedersen, B. K.; Ruderman, N. B. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise Biochem. Biophys. Res. Commun. 2004, 320, 449-454
109. Saha, A. K.; Avilucea, P. R.; Ye, J. M.; Assifi, M. M.; Kraegen, E. W.; Ruderman, N. B. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo Biochem. Biophys. Res. Commun. 2004, 314, 580-585
110. Gómez-Galeno, J. E.; Nguyen, T. H.; Boyer, S. H.; Grote, M. P.; Sun, Z.; Chen, M.; Craigo, W. A.; van Poelje, P. D.; MacKenna, D. A.; Cable, E. E.; Rolzin, P. A.; Finn, P. D.; Chi, B.; Linemeyer, D. L.; Hecker, S. J.; Erion, M. D. A potent and selective AMPK activator that inhibits de novo lipogenesis ACS Med. Chem. Lett. 2010, 1, 478-482
111. Halseth, A. E.; Ensor, N. J.; White, T. A.; Ross, S. A.; Gulve, E. A. Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations Biochem. Biophys. Res. Commun. 2002, 294, 798-805
112. Crowther, R. A. Structural aspects of pathology in Alzheimer's disease Biochim. Biophys. Acta 1990, 1096, 1-9
113. Wirths, O.; Multhaup, G.; Bayer, T. A. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade J. Neurochem. 2004, 91, 513-520
114. Erol, A. An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease J. Alzheimer's Dis. 2008, 13, 241-253
115. Poels, J.; Spasic, M. R.; Callaerts, P.; Norga, K. K. Expanding roles for AMP-activated protein kinase in neuronal survival and autophagy BioEssays 2009, 31, 944-952
116. Vingtdeux, V.; Davies, P.; Dickson, D. W.; Marambaud, P. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies Acta Neuropathol. 2011, 121, 337-349
117. Vingtdeux, V.; Dreses-Werringloer, U.; Zhao, H.; Davies, P.; Marambaud, P. Therapeutic potential of resveratrol in Alzheimer's disease BMC Neurosci. 2008, 9 (Suppl. 2) S6
118. Greco, S. J.; Sarkar, S.; Johnston, J. M.; Tezapsidis, N. Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells Biochem. Biophys. Res. Commun. 2009, 380, 98-104
119. Chen, Y.; Zhou, K.; Wang, R.; Liu, Y.; Kwak, Y. D.; Ma, T.; Thompson, R. C.; Zhao, Y.; Smith, L.; Gasparini, L.; Luo, Z.; Xu, H.; Liao, F. F. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 3907-3912
120. Lee, V. M.; Balin, B. J.; Otvos, L., Jr.; Trojanowski, J. Q. Ab: a major subunit of paired helical filaments and derivatized forms of normal Tau Science 1991, 251, 675-678
121. Johnson, G. V.; Stoothoff, W. H. Tau phosphorylation in neuronal cell function and dysfunction J. Cell Sci. 2004, 117, 5721-5729
122. Goedert, M.; Hasegawa, M.; Jakes, R.; Lawler, S.; Cuenda, A.; Cohen, P. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases FEBS Lett. 1997, 409, 57-62
123. Sengupta, A.; Grundke-Iqbal, I.; Iqbal, K. Regulation of phosphorylation of tau by protein kinases in rat brain Neurochem. Res. 2006, 31, 1473-1480
124. Flaherty, D. B.; Soria, J. P.; Tomasiewicz, H. G.; Wood, J. G. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants J. Neurosci. Res. 2000, 62, 463-472
125. Scales, T. M.; Derkinderen, P.; Leung, K. Y.; Byers, H. L.; Ward, M. A.; Price, C.; Bird, I. N.; Perera, T.; Kellie, S.; Williamson, R.; Anderton, B. H.; Reynolds, C. H. Tyrosine phosphorylation of tau by the SRC family kinases lck and fyn Mol. Neurodegener. 2011, 6, 12
126. Thornton, C.; Bright, N. J.; Sastre, M.; Muckett, P. J.; Carling, D. AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid beta-peptide exposure Biochem. J. 2011, 434, 503-512
127. Park, H.; Kam, T. I.; Kim, Y.; Choi, H.; Gwon, Y.; Kim, C.; Koh, J. Y.; Jung, Y. K. Neuropathogenic role of adenylate kinase-1 in Abeta-mediated tau phosphorylation via AMPK and GSK3beta Hum. Mol. Genet. 2012, 21, 2725-2737
128. Yu, J. T.; Chang, R. C.; Tan, L. Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic opportunities Prog. Neurobiol. 2009, 89, 240-255
129. Min, S. W.; Cho, S. H.; Zhou, Y.; Schroeder, S.; Haroutunian, V.; Seeley, W. W.; Huang, E. J.; Shen, Y.; Masliah, E.; Mukherjee, C.; Meyers, D.; Cole, P. A.; Ott, M.; Gan, L. Acetylation of tau inhibits its degradation and contributes to tauopathy Neuron 2010, 67, 953-966
130. Greco, S. J.; Sarkar, S.; Casadesus, G.; Zhu, X.; Smith, M. A.; Ashford, J. W.; Johnston, J. M.; Tezapsidis, N. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells Neurosci. Lett. 2009, 455, 191-194
131. Kim, J.; Park, Y. J.; Jang, Y.; Kwon, Y. H. AMPK activation inhibits apoptosis and tau hyperphosphorylation mediated by palmitate in SH-SY5Y cells Brain Res. 2011, 1418, 42-51
132. McCullough, L. D.; Zeng, Z.; Li, H.; Landree, L. E.; McFadden, J.; Ronnett, G. V. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke J. Biol. Chem. 2005, 280, 20493-20502
133. Li, J.; Zeng, Z.; Viollet, B.; Ronnett, G. V.; McCullough, L. D. Neuroprotective effects of adenosine monophosphate-activated protein kinase inhibition and gene deletion in stroke Stroke 2007, 38, 2992-2999
134. Ronnett, G. V.; Ramamurthy, S.; Kleman, A. M.; Landree, L. E.; Aja, S. AMPK in the brain: its roles in energy balance and neuroprotection J. Neurochem. 2009, 109 (Suppl. 1) 17-23
135. Li, J.; Benashski, S.; McCullough, L. D. Post-stroke hypothermia provides neuroprotection through inhibition of AMP-activated protein kinase J. Neurotrauma 2011, 28, 1281-1218
136. Ju, T. C.; Chen, H. M.; Lin, J. T.; Chang, C. P.; Chang, W. C.; Kang, J. J.; Sun, C. P.; Tao, M. H.; Tu, P. H.; Chang, C.; Dickson, D. W.; Chern, Y. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease J. Cell Biol. 2011, 194, 209-227
137. Goldthwait, D. A.; Greenberg, G. R.; Peabody, R. A. The structure of glycinamide ribotide J. Biol. Chem. 1956, 221, 1071-1081
138. Goldthwait, D. A.; Greenberg, G. R.; Peabody, R. A. On the mechanism of synthesis of glycinamide ribotide and its formyl derivative J. Biol. Chem. 1956, 221, 569-577
139. Goldthwait, D. A.; Greenberg, G. R.; Peabody, R. A. On the occurrence of glycinamide ribotide and its formyl derivative J. Biol. Chem. 1956, 221, 555-567
140. Sabina, R. L.; Patterson, D.; Holmes, E. W. 5-Amino-4-imidazolecarboxamide riboside (Z-riboside) metabolism in eukaryotic cells J. Biol. Chem. 1985, 260, 6107-6714
141. Schnebli, H. P.; Hill, D. L.; Bennett, L. L., Jr. Purification and properties of adenosine kinase from human tumor cells of type H. Ep. No. 2 J. Biol. Chem. 1967, 242, 1997-2004
142. Sabina, R. L.; Kernstine, K. H.; Boyd, R. L.; Holmes, E. W.; Swain, J. L. Metabolism of 5-amino-4-imidazolecarboxamide riboside in cardiac and skeletal muscle. Effects on purine nucleotide synthesis J. Biol. Chem. 1982, 257, 10178-10183
143. Swain, J. L.; Hines, J. J.; Sabina, R. L.; Harbury, O. L.; Holmes, E. W. Disruption of the purine nucleotide cycle by inhibition of adenylosuccinate lyase produces skeletal muscle dysfunction J. Clin. Invest. 1984, 74, 1422-1427
144. Sullivan, J. E.; Carey, F.; Carling, D.; Beri, R. K. Characterisation of 5′-AMP-activated protein kinase in human liver using specific peptide substrates and the effects of 5′-AMP analogues on enzyme activity Biochem. Biophys. Res. Commun. 1994, 200, 1551-1556
145. Day, P.; Sharff, A.; Parra, L.; Cleasby, A.; Williams, M.; Horer, S.; Nar, H.; Redemann, N.; Tickle, I.; Yon, J. Structure of a CBS-domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP and ZMP Acta Crystallogr., Sect. D: Biol. Crystallogr. 2007, 63, 587-596
146. Henin, N.; Vincent, M. F.; Van den Berghe, G. Stimulation of rat liver AMP-activated protein kinase by AMP analogues Biochim. Biophys. Acta 1996, 1290, 197-203
147. Corton, J. M.; Gillespie, J. G.; Hardie, D. G. Role of the AMP-activated protein kinase in the cellular stress response Curr. Biol. 1994, 4, 315-324
148. Henin, N.; Vincent, M. F.; Gruber, H. E.; Van den Berghe, G. Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase FASEB J. 1995, 9, 541-546
149. Hayashi, T.; Hirshman, M. F.; Kurth, E. J.; Winder, W. W.; Goodyear, L. J. Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport Diabetes 1998, 47, 1369-1373
150. Hayashi, T.; Hirshman, M. F.; Fujii, N.; Habinowski, S. A.; Witters, L. A.; Goodyear, L. J. Metabolic stress and altered glucose transport: activation of AMP-activated protein kinase as a unifying coupling mechanism Diabetes 2000, 49, 527-531
151. Bergeron, R.; Previs, S. F.; Cline, G. W.; Perret, P.; Russell, R. R., 3rd; Young, L. H.; Shulman, G. I. Effect of 5-aminoimidazole-4-carboxamide-1-beta- d -ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats Diabetes 2001, 50, 1076-1082
152. Vincent, M. F.; Erion, M. D.; Gruber, H. E.; Van den Berghe, G. Hypoglycaemic effect of AICAriboside in mice Diabetologia 1996, 39, 1148-1155
153. Mu, J.; Brozinick, J. T., Jr.; Valladares, O.; Bucan, M.; Birnbaum, M. J. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle Mol. Cell 2001, 7, 1085-1094
154. Sylow, L.; Jensen, T. E.; Kleinert, M.; Hojlund, K.; Kiens, B.; Wojtaszewski, J.; Prats, C.; Schjerling, P.; Richter, E. A. Rac1 signaling is required for insulin-stimulated glucose uptake and is dysregulated in insulin-resistant murine and human skeletal muscle Diabetes 2013, 62, 1865-1875
155. Russell, R. R., 3rd; Bergeron, R.; Shulman, G. I.; Young, L. H. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR Am. J. Physiol. 1999, 277, H643-649
156. Bergeron, R.; Russell, R. R., 3rd; Young, L. H.; Ren, J. M.; Marcucci, M.; Lee, A.; Shulman, G. I. Effect of AMPK activation on muscle glucose metabolism in conscious rats Am. J. Physiol. 1999, 276, E938-944
157. Rattan, R.; Giri, S.; Singh, A. K.; Singh, I. 5-Aminoimidazole-4-carboxamide-1-beta- d -ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase J. Biol. Chem. 2005, 280, 39582-39593
158. Imamura, K.; Ogura, T.; Kishimoto, A.; Kaminishi, M.; Esumi, H. Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta- d -ribofuranoside, in a human hepatocellular carcinoma cell line Biochem. Biophys. Res. Commun. 2001, 287, 562-567
159. Gleason, C. E.; Lu, D.; Witters, L. A.; Newgard, C. B.; Birnbaum, M. J. The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells J. Biol. Chem. 2007, 282, 10341-10351
160. Nakamura, J. L.; Garcia, E.; Pieper, R. O. S6K1 plays a key role in glial transformation Cancer Res. 2008, 68, 6516-6523
161. Choe, G.; Horvath, S.; Cloughesy, T. F.; Crosby, K.; Seligson, D.; Palotie, A.; Inge, L.; Smith, B. L.; Sawyers, C. L.; Mischel, P. S. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo Cancer Res. 2003, 63, 2742-2746
162. Carracedo, A.; Ma, L.; Teruya-Feldstein, J.; Rojo, F.; Salmena, L.; Alimonti, A.; Egia, A.; Sasaki, A. T.; Thomas, G.; Kozma, S. C.; Papa, A.; Nardella, C.; Cantley, L. C.; Baselga, J.; Pandolfi, P. P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J. Clin. Invest. 2008, 118, 3065-3074
163. Guo, D.; Hildebrandt, I. J.; Prins, R. M.; Soto, H.; Mazzotta, M. M.; Dang, J.; Czernin, J.; Shyy, J. Y.; Watson, A. D.; Phelps, M.; Radu, C. G.; Cloughesy, T. F.; Mischel, P. S. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 12932-12937
164. Cool, B.; Zinker, B.; Chiou, W.; Kifle, L.; Cao, N.; Perham, M.; Dickinson, R.; Adler, A.; Gagne, G.; Iyengar, R.; Zhao, G.; Marsh, K.; Kym, P.; Jung, P.; Camp, H. S.; Frevert, E. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome Cell Metab. 2006, 3, 403-416
165. Longnus, S. L.; Wambolt, R. B.; Parsons, H. L.; Brownsey, R. W.; Allard, M. F. 5-Aminoimidazole-4-carboxamide 1-beta- d -ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms Am. J. Physiol.: Regul., Integr. Comp. Physiol. 2003, 284, R936-R944
166. Vincent, M. F.; Marangos, P. J.; Gruber, H. E.; Van den Berghe, G. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes Diabetes 1991, 40, 1259-1266
167. Young, M. E.; Radda, G. K.; Leighton, B. Activation of glycogen phosphorylase and glycogenolysis in rat skeletal muscle by AICAR - an activator of AMP-activated protein kinase FEBS Lett. 1996, 382, 43-47
168. Scott, J. W.; van Denderen, B. J.; Jorgensen, S. B.; Honeyman, J. E.; Steinberg, G. R.; Oakhill, J. S.; Iseli, T. J.; Koay, A.; Gooley, P. R.; Stapleton, D.; Kemp, B. E. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes Chem. Biol. 2008, 15, 1220-1230
169. Sanders, M. J.; Ali, Z. S.; Hegarty, B. D.; Heath, R.; Snowden, M. A.; Carling, D. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family J. Biol. Chem. 2007, 282, 32539-32548
170. Hallakou-Bozec, S.; Charon, C.; Hock, B.; Poeschke, O. Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them. WO2007019914, 2007; Merck Patent GMBH.
171. Cravo, D.; Lepifre, F.; Hallakou-Bozec, S.; Charon, C. Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators and their preparation, pharmaceutical compositions, and use in the treatment of diseases. WO2009124636, 2009; Merck Patent GMBH.
172. Cravo, D.; Lepifre, F.; Hallakou-Bozec, S.; Charon, C. Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators. WO2009135580, 2009; Merck Patent GMBH.
173. Moinet, G.; Marais, D.; Hallakou-Bozec, S.; Charon, C. Use of AMPK-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them. WO2008006432, 2008; Merck Patent GMBH.
174. Birnberg, N. C.; Liu, H.; Weng, Q. P.; Shang, H.; Yin, P.; Rajur, S. B.; Kim, H.-O.; Salgaonkar, P. D.; Peet, N. P. AMPK modulators. WO2009100130, 2009; Mercury Therapeutics, Inc.
175. Mirguet, O.; Sautet, S.; Clément, C.-A.; Toum, J.; Donche, F.; Marques, C.; Rondet, E.; Pizzonero, M.; Beaufils, B.; Dudit, Y.; Huet, P.; Trottet, L.; Grondin, P.; Brusq, J.-M.; Boursier, E.; Saintillan, Y.; Nicodeme, E. Discovery of pyridones as oral AMPK direct activators ACS Med. Chem. Lett. 2013, 4, 632-636
176. Bookser, B. C.; Dang, Q.; Gibson, T. S.; Jiang, H.; Chung, D. M.; Bao, J.; Jiang, J.; Kassick, A.; Kekec, A.; Lan, P.; Lu, H.; Makara, G. M.; Romero, F. A.; Sebhat, I.; Wilson, D.; Wodka, D. Novel cyclic benzimidazole derivatives useful anti-diabetic agents. WO2010036613, 2010; Merck Sharp & Dohme Corp. and Metathesis Therapeutics, Inc.
177. Bookser, B. C.; Dang, Q.; Gibson, T. S.; Jiang, H.; Chung, D. M.; Bao, J.; Jiang, J.; Kassick, A.; Kekec, A.; Lan, P.; Lu, H.; Makara, G. M.; Romero, F. A.; Sebhat, I.; Wilson, D.; Wodka, D. Novel cyclic benzimidazole derivatives useful anti-diabetic agents. WO2010047982 2010; Merck Sharp & Dohme Corp. and Metabasis Therapeutics, Inc.
178. Dang, Q.; Chung, D. M.; Gibson, T. S.; Jiang, H.; Cashion, D. K.; Bao, J.; Lan, P.; Lu, H.; Makara, G. M.; Romero, F. A.; Sebhat, I.; Wodka, D. Novel cyclic benzimidazole derivatives useful anti-diabetic agents. WO2010051176, 2010; Merck Sharp & Dohme Corp. and Metabasis Therapeutics, Inc.
179. Dang, Q.; Chung, D. M.; Gibson, T. S.; Jiang, H.; Cashion, D. K.; Bao, J.; Lan, P.; Lu, H.; Makara, G. M.; Romero, F. A.; Sebhat, I.; Wodka, D. Novel cyclic benzimidazole derivatives as AMP-activated protein kinase activators and anti-diabetic agents and their preparation. WO2010051206, 2010; Merck Sharp & Dohme Corp. and Metabasis Therapeutics, Inc.
180. Jiang, J.; Kassick, A. J.; Kekec, A.; Sebhat, I. K. Novel cyclic benzimidazole derivatives useful anti-diabetic agents. WO2011106273, 2011; Merck Sharp & Dohme Corp.
181. Pang, T.; Zhang, Z. S.; Gu, M.; Qiu, B. Y.; Yu, L. F.; Cao, P. R.; Shao, W.; Su, M. B.; Li, J. Y.; Nan, F. J.; Li, J. Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells J. Biol. Chem. 2008, 283, 16051-16060
182. Yu, L.-F.; Li, Y.-Y.; Su, M.-B.; Zhang, M.; Zhang, W.; Zhang, L.-N.; Pang, T.; Zhang, R.-T.; Liu, B.; Li, J.-Y.; Li, J.; Nan, F.-J. Development of novel alkene oxindole derivatives as orally efficacious AMP-activated protein kinase activators ACS Med. Chem. Lett. 2013, 4, 475-480
183. Li, Y. Y.; Yu, L. F.; Zhang, L. N.; Qiu, B. Y.; Su, M. B.; Wu, F.; Chen, D. K.; Pang, T.; Gu, M.; Zhang, W.; Ma, W. P.; Jiang, H. W.; Li, J. Y.; Nan, F. J.; Li, J. Novel small-molecule AMPK activator orally exerts beneficial effects on diabetic db/db mice Toxicol. Appl. Pharmacol. 2013, 273, 325-334
184. Nan, F.; Yu, L.; Zhang, M.; Chen, L.; Huang, M.; Feng, L.; Li, J.; Pang, T. Novel alkene oxindole derivatives. WO2011032320, 2011; F. Hoffmann-La Roche AG.
185. Chen, L.; Feng, L.; Huang, M.; Li, J.; Nan, F.; Pang, T.; Yu, L.; Zhang, M. Alkene oxindole derivatives and their uses to treat obesity, diabetes and hyperlipidemia. WO2011033099, 2011; F. Hoffmann-La Roche AG.
186. Chen, L.; Huang, M.; Feng, L.; He, Y.; Yun, H. Novel cyclopropane indolinone derivatives. WO2011069298, 2011; F. Hoffmann-La Roche AG.
187. Chen, L.; Feng, L.; He, Y.; Huang, M.; Yun, H. Sprio indole-cyclopropane indolinones useful as AMPK modulators. WO2011070039, 2011; F. Hoffmann-La Roche AG.
188. Reymond, P.; Farmer, E. E. Jasmonate and salicylate as global signals for defense gene expression Curr. Opin. Plant Biol. 1998, 1, 404-411
189. Hawley, S. A.; Fullerton, M. D.; Ross, F. A.; Schertzer, J. D.; Chevtzoff, C.; Walker, K. J.; Peggie, M. W.; Zibrova, D.; Green, K. A.; Mustard, K. J.; Kemp, B. E.; Sakamoto, K.; Steinberg, G. R.; Hardie, D. G. The ancient drug salicylate directly activates AMP-activated protein kinase Science 2012, 336, 918-922
190. Din, F. V.; Valanciute, A.; Houde, V. P.; Zibrova, D.; Green, K. A.; Sakamoto, K.; Alessi, D. R.; Dunlop, M. G. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells Gastroenterology 2012, 142, 1504-1515
191. Choi, J.; He, N.; Sung, M. K.; Yang, Y.; Yoon, S. Sanguinarine is an allosteric activator of AMP-activated protein kinase Biochem. Biophys. Res. Commun. 2011, 413, 259-263
192. Bailey, C. J.; Turner, R. C. Metformin N. Engl. J. Med. 1996, 334, 574-579
193. Stumvoll, M.; Nurjhan, N.; Perriello, G.; Dailey, G.; Gerich, J. E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus N. Engl. J. Med. 1995, 333, 550-554
194. Hundal, R. S.; Krssak, M.; Dufour, S.; Laurent, D.; Lebon, V.; Chandramouli, V.; Inzucchi, S. E.; Schumann, W. C.; Petersen, K. F.; Landau, B. R.; Shulman, G. I. Mechanism by which metformin reduces glucose production in type 2 diabetes Diabetes 2000, 49, 2063-2069
195. Hundal, H. S.; Ramlal, T.; Reyes, R.; Leiter, L. A.; Klip, A. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells Endocrinology 1992, 131, 1165-1173
196. Galuska, D.; Nolte, L. A.; Zierath, J. R.; Wallberg-Henriksson, H. Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM Diabetologia 1994, 37, 826-832
197. Shimomura, I.; Matsuda, M.; Hammer, R. E.; Bashmakov, Y.; Brown, M. S.; Goldstein, J. L. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice Mol. Cell 2000, 6, 77-86
198. Shaw, R. J.; Lamia, K. A.; Vasquez, D.; Koo, S. H.; Bardeesy, N.; Depinho, R. A.; Montminy, M.; Cantley, L. C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin Science 2005, 310, 1642-1646
199. Jin, H. E.; Hong, S. S.; Choi, M. K.; Maeng, H. J.; Kim, D. D.; Chung, S. J.; Shim, C. K. Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis Pharm. Res. 2009, 26, 549-559
200. Shu, Y.; Sheardown, S. A.; Brown, C.; Owen, R. P.; Zhang, S.; Castro, R. A.; Ianculescu, A. G.; Yue, L.; Lo, J. C.; Burchard, E. G.; Brett, C. M.; Giacomini, K. M. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action J. Clin. Invest. 2007, 117, 1422-1431
201. Vingtdeux, V.; Giliberto, L.; Zhao, H.; Chandakkar, P.; Wu, Q.; Simon, J. E.; Janle, E. M.; Lobo, J.; Ferruzzi, M. G.; Davies, P.; Marambaud, P. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism J. Biol. Chem. 2010, 285, 9100-9113
202. Vingtdeux, V.; Chandakkar, P.; Zhao, H.; d'Abramo, C.; Davies, P.; Marambaud, P. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-beta peptide degradation FASEB J. 2011, 25, 219-231
203. Howitz, K. T.; Bitterman, K. J.; Cohen, H. Y.; Lamming, D. W.; Lavu, S.; Wood, J. G.; Zipkin, R. E.; Chung, P.; Kisielewski, A.; Zhang, L. L.; Scherer, B.; Sinclair, D. A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan Nature 2003, 425, 191-196
204. Borra, M. T.; Smith, B. C.; Denu, J. M. Mechanism of human SIRT1 activation by resveratrol J. Biol. Chem. 2005, 280, 17187-17195
205. Gu, X. S.; Wang, Z. B.; Ye, Z.; Lei, J. P.; Li, L.; Su, D. F.; Zheng, X. Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure Genet. Mol. Res. 2014, 13, 323-335
206. Pacholec, M.; Bleasdale, J. E.; Chrunyk, B.; Cunningham, D.; Flynn, D.; Garofalo, R. S.; Griffith, D.; Griffor, M.; Loulakis, P.; Pabst, B.; Qiu, X.; Stockman, B.; Thanabal, V.; Varghese, A.; Ward, J.; Withka, J.; Ahn, K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1 J. Biol. Chem. 2010, 285, 8340-8351
207. Beher, D.; Wu, J.; Cumine, S.; Kim, K. W.; Lu, S. C.; Atangan, L.; Wang, M. Resveratrol is not a direct activator of SIRT1 enzyme activity Chem. Biol. Drug Des. 2009, 74, 619-624
208. Desquiret-Dumas, V.; Gueguen, N.; Leman, G.; Baron, S.; Nivet-Antoine, V.; Chupin, S.; Chevrollier, A.; Vessieres, E.; Ayer, A.; Ferre, M.; Bonneau, D.; Henrion, D.; Reynier, P.; Procaccio, V. Resveratrol induces a mitochondrial complex I-dependent increase in NADH oxidation responsible for sirtuin activation in liver cells J. Biol. Chem. 2013, 288, 36662-36675
209. Strobel, P.; Allard, C.; Perez-Acle, T.; Calderon, R.; Aldunate, R.; Leighton, F. Myricetin, quercetin and catechin-gallate inhibit glucose uptake in isolated rat adipocytes Biochem. J. 2005, 386, 471-478
210. Ahn, J.; Lee, H.; Kim, S.; Park, J.; Ha, T. The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways Biochem. Biophys. Res. Commun. 2008, 373, 545-549
211. Lee, S. M.; Moon, J.; Cho, Y.; Chung, J. H.; Shin, M. J. Quercetin up-regulates expressions of peroxisome proliferator-activated receptor gamma, liver X receptor alpha, and ATP binding cassette transporter A1 genes and increases cholesterol efflux in human macrophage cell line Nutr. Res. (N. Y., NY, U. S.) 2013, 33, 136-143
212. Guo, H.; Zhao, H.; Kanno, Y.; Li, W.; Mu, Y.; Kuang, X.; Inouye, Y.; Koike, K.; Jiang, H.; Bai, H. A dihydrochalcone and several homoisoflavonoids from Polygonatum odoratum are activators of adenosine monophosphate-activated protein kinase Bioorg. Med. Chem. Lett. 2013, 23, 3137-3139
213. Deng, Y.; He, K.; Ye, X.; Chen, X.; Huang, J.; Li, X.; Yuan, L.; Jin, Y.; Jin, Q.; Li, P. Saponin rich fractions from Polygonatum odoratum (Mill.) Druce with more potential hypoglycemic effects J. Ethnopharmacol. 2012, 141, 228-233
214. Choi, S. B.; Park, S. A steroidal glycoside from Polygonatum odoratum (Mill.) Druce. improves insulin resistance but does not alter insulin secretion in 90% pancreatectomized rats Biosci Biotechnol Biochem 2002, 66, 2036-2043
215. Cheng, Z.; Pang, T.; Gu, M.; Gao, A. H.; Xie, C. M.; Li, J. Y.; Nan, F. J.; Li, J. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK Biochim. Biophys. Acta 2006, 1760, 1682-1689
216. Lau, C. W.; Yao, X. Q.; Chen, Z. Y.; Ko, W. H.; Huang, Y. Cardiovascular actions of berberine Cardiovasc. Drug Rev. 2001, 19, 234-244
217. Lee, Y. S.; Kim, W. S.; Kim, K. H.; Yoon, M. J.; Cho, H. J.; Shen, Y.; Ye, J. M.; Lee, C. H.; Oh, W. K.; Kim, C. T.; Hohnen-Behrens, C.; Gosby, A.; Kraegen, E. W.; James, D. E.; Kim, J. B. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states Diabetes 2006, 55, 2256-2564
218. Matthews, D. R.; Hosker, J. P.; Rudenski, A. S.; Naylor, B. A.; Treacher, D. F.; Turner, R. C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 1985, 28, 412-419
219. Mikes, V.; Yaguzhinskij, L. S. Interaction of fluorescent berberine alkyl derivatives with respiratory chain of rat liver mitochondria J. Bioenerg. Biomembr. 1985, 17, 23-32
220. Ni, Y. X. Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research Zhong Xi Yi Jie He Za Zhi 1988, 8, 711-713
221. Sack, R. B.; Froehlich, J. L. Berberine inhibits intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins Infect. Immun. 1982, 35, 471-475
222. Sanders, M. J.; Grondin, P. O.; Hegarty, B. D.; Snowden, M. A.; Carling, D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade Biochem. J. 2007, 403, 139-148
223. Turner, N.; Li, J. Y.; Gosby, A.; To, S. W.; Cheng, Z.; Miyoshi, H.; Taketo, M. M.; Cooney, G. J.; Kraegen, E. W.; James, D. E.; Hu, L. H.; Li, J.; Ye, J. M. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action Diabetes 2008, 57, 1414-1418
224. Yin, J.; Gao, Z.; Liu, D.; Liu, Z.; Ye, J. Berberine improves glucose metabolism through induction of glycolysis Am. J. Physiol.: Endocrinol. Metab. 2008, 294, E148-E156
225. Owen, M. R.; Doran, E.; Halestrap, A. P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain Biochem. J. 2000, 348 (Part 3) 607-614
226. Brunmair, B.; Staniek, K.; Gras, F.; Scharf, N.; Althaym, A.; Clara, R.; Roden, M.; Gnaiger, E.; Nohl, H.; Waldhausl, W.; Furnsinn, C. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 2004, 53, 1052-1059
227. El-Mir, M. Y.; Nogueira, V.; Fontaine, E.; Averet, N.; Rigoulet, M.; Leverve, X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I J. Biol. Chem. 2000, 275, 223-228
228. Yin, J.; Xing, H.; Ye, J. Efficacy of berberine in patients with type 2 diabetes mellitus Metabolism 2008, 57, 712-717
229. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J. Biol. Chem. 1995, 270, 12953-12956
230. Willson, T. M.; Cobb, J. E.; Cowan, D. J.; Wiethe, R. W.; Correa, I. D.; Prakash, S. R.; Beck, K. D.; Moore, L. B.; Kliewer, S. A.; Lehmann, J. M. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones J. Med. Chem. 1996, 39, 665-668
231. Hallakou, S.; Doare, L.; Foufelle, F.; Kergoat, M.; Guerre-Millo, M.; Berthault, M. F.; Dugail, I.; Morin, J.; Auwerx, J.; Ferre, P. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat Diabetes 1997, 46, 1393-1399
232. Palakurthi, S. S.; Aktas, H.; Grubissich, L. M.; Mortensen, R. M.; Halperin, J. A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation Cancer Res. 2001, 61, 6213-6218
233. Fan, Y. H.; Chen, H.; Natarajan, A.; Guo, Y.; Harbinski, F.; Iyasere, J.; Christ, W.; Aktas, H.; Halperin, J. A. Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium Bioorg. Med. Chem. Lett. 2004, 14, 2547-2550
234. Chen, H.; Fan, Y. H.; Natarajan, A.; Guo, Y.; Iyasere, J.; Harbinski, F.; Luus, L.; Christ, W.; Aktas, H.; Halperin, J. A. Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation Bioorg. Med. Chem. Lett. 2004, 14, 5401-5405
235. Saltiel, A. R.; Olefsky, J. M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes Diabetes 1996, 45, 1661-1669
236. Balfour, J. A.; Plosker, G. L. Rosiglitazone Drugs 1999, 57, 921-930 (discussion 931-932)
237. Fryer, L. G.; Parbu-Patel, A.; Carling, D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways J. Biol. Chem. 2002, 277, 25226-25232
238. Guh, J. H.; Chang, W. L.; Yang, J.; Lee, S. L.; Wei, S.; Wang, D.; Kulp, S. K.; Chen, C. S. Development of novel adenosine monophosphate-activated protein kinase activators J. Med. Chem. 2010, 53, 2552-2561
239. Diaz, N.; Minton, S.; Cox, C.; Bowman, T.; Gritsko, T.; Garcia, R.; Eweis, I.; Wloch, M.; Livingston, S.; Seijo, E.; Cantor, A.; Lee, J. H.; Beam, C. A.; Sullivan, D.; Jove, R.; Muro-Cacho, C. A. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression Clin. Cancer Res. 2006, 12, 20-28
240. Shen, Z.; Wen, X. F.; Lan, F.; Shen, Z. Z.; Shao, Z. M. The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma Clin. Cancer Res. 2002, 8, 2085-2090
241. Lambert, J. D.; Yang, C. S. Mechanisms of cancer prevention by tea constituents J. Nutr. 2003, 133, 3262S-3267S
242. Wolfram, S.; Raederstorff, D.; Preller, M.; Wang, Y.; Teixeira, S. R.; Riegger, C.; Weber, P. Epigallocatechin gallate supplementation alleviates diabetes in rodents J. Nutr. 2006, 136, 2512-2518
243. Wolfram, S.; Wang, Y.; Thielecke, F. Anti-obesity effects of green tea: from bedside to bench Mol. Nutr. Food Res. 2006, 50, 176-187
244. Collins, Q. F.; Liu, H. Y.; Pi, J.; Liu, Z.; Quon, M. J.; Cao, W. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5′-AMP-activated protein kinase J. Biol. Chem. 2007, 282, 30143-30149
245. Hwang, J. T.; Ha, J.; Park, I. J.; Lee, S. K.; Baik, H. W.; Kim, Y. M.; Park, O. J. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway Cancer Lett. 2007, 247, 115-121
246. Chen, Z.; Zhu, Q. Y.; Tsang, D.; Huang, Y. Degradation of green tea catechins in tea drinks J. Agric. Food Chem. 2001, 49, 477-482
247. Lu, H.; Meng, X.; Yang, C. S. Enzymology of methylation of tea catechins and inhibition of catechol- O -methyltransferase by (-)-epigallocatechin gallate Drug Metab. Dispos. 2003, 31, 572-579
248. Landis-Piwowar, K. R.; Huo, C.; Chen, D.; Milacic, V.; Shi, G.; Chan, T. H.; Dou, Q. P. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent Cancer Res. 2007, 67, 4303-4210
249. Chen, D.; Pamu, S.; Cui, Q.; Chan, T. H.; Dou, Q. P. Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells Bioorg. Med. Chem. 2012, 20, 3031-3037
250. Pan, W.; Yang, H.; Cao, C.; Song, X.; Wallin, B.; Kivlin, R.; Lu, S.; Hu, G.; Di, W.; Wan, Y. AMPK mediates curcumin-induced cell death in CaOV3 ovarian cancer cells Oncol. Rep. 2008, 20, 1553-1559
251. Ireson, C.; Orr, S.; Jones, D. J.; Verschoyle, R.; Lim, C. K.; Luo, J. L.; Howells, L.; Plummer, S.; Jukes, R.; Williams, M.; Steward, W. P.; Gescher, A. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production Cancer Res. 2001, 61, 1058-1064
252. Hung, C. M.; Su, Y. H.; Lin, H. Y.; Lin, J. N.; Liu, L. C.; Ho, C. T.; Way, T. D. Demethoxycurcumin modulates prostate cancer cell proliferation via AMPK-induced down-regulation of HSP70 and EGFR J. Agric. Food Chem. 2012, 60, 8427-8434
253. Lee, W. J.; Song, K. H.; Koh, E. H.; Won, J. C.; Kim, H. S.; Park, H. S.; Kim, M. S.; Kim, S. W.; Lee, K. U.; Park, J. Y. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle Biochem. Biophys. Res. Commun. 2005, 332, 885-891
254. Shen, Q. W.; Zhu, M. J.; Tong, J.; Ren, J.; Du, M. Ca2+/calmodulin-dependent protein kinase kinase is involved in AMP-activated protein kinase activation by alpha-lipoic acid in C2C12 myotubes Am. J. Physiol.: Cell Physiol. 2007, 293, C1395-C1403
255. Lee, Y.; Naseem, R. H.; Park, B. H.; Garry, D. J.; Richardson, J. A.; Schaffer, J. E.; Unger, R. H. Alpha-lipoic acid prevents lipotoxic cardiomyopathy in acyl CoA-synthase transgenic mice Biochem. Biophys. Res. Commun. 2006, 344, 446-452
256. Targonsky, E. D.; Dai, F.; Koshkin, V.; Karaman, G. T.; Gyulkhandanyan, A. V.; Zhang, Y.; Chan, C. B.; Wheeler, M. B. Alpha-lipoic acid regulates AMP-activated protein kinase and inhibits insulin secretion from beta cells Diabetologia 2006, 49, 1587-1598
257. Park, K. G.; Min, A. K.; Koh, E. H.; Kim, H. S.; Kim, M. O.; Park, H. S.; Kim, Y. D.; Yoon, T. S.; Jang, B. K.; Hwang, J. S.; Kim, J. B.; Choi, H. S.; Park, J. Y.; Lee, I. K.; Lee, K. U. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways Hepatology 2008, 48, 1477-1486
258. Tang, X.; Zhuang, J.; Chen, J.; Yu, L.; Hu, L.; Jiang, H.; Shen, X. Arctigenin efficiently enhanced sedentary mice treadmill endurance PLoS One 2011, 6, e24224
259. Shen, S.; Zhuang, J.; Chen, Y.; Lei, M.; Chen, J.; Shen, X.; Hu, L. Synthesis and biological evaluation of arctigenin ester and ether derivatives as activators of AMPK Bioorg. Med. Chem. 2013, 21, 3882-3893
260. Way, T. D.; Lee, J. C.; Kuo, D. H.; Fan, L. L.; Huang, C. H.; Lin, H. Y.; Shieh, P. C.; Kuo, P. T.; Liao, C. F.; Liu, H.; Kao, J. Y. Inhibition of epidermal growth factor receptor signaling by Saussurea involucrata, a rare traditional Chinese medicinal herb, in human hormone-resistant prostate cancer PC-3 cells J. Agric. Food Chem. 2010, 58, 3356-3365
261. Yang, J. M.; Hung, C. M.; Fu, C. N.; Lee, J. C.; Huang, C. H.; Yang, M. H.; Lin, C. L.; Kao, J. Y.; Way, T. D. Hispidulin sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by AMPK activation leading to Mcl-1 block in translation J. Agric. Food Chem. 2010, 58, 10020-10026
262. Sviripa, V.; Zhang, W.; Conroy, M. D.; Schmidt, E. S.; Liu, A. X.; Truong, J.; Liu, C.; Watt, D. S. Fluorinated N, N ′-diarylureas as AMPK activators Bioorg. Med. Chem. Lett. 2013, 23, 1600-1603
263. Sartore-Bianchi, A.; Zeppellini, A.; Amatu, A.; Ricotta, R.; Bencardino, K.; Siena, S. Regorafenib in metastatic colorectal cancer Expert Rev. Anticancer Ther 2014, 14, 255-265
264. Procopio, G.; Derosa, L.; Gernone, A.; Morelli, F.; Sava, T.; Zustovich, F.; De Giorgi, U.; Ferrari, V.; Sabbatini, R.; Gasparro, D.; Felici, A.; Burattini, L.; Calvani, N.; Lo Re, G.; Banna, G.; Brizzi, M. P.; Rizzo, M.; Ciuffreda, L.; Iacovelli, R.; Ferrau, F.; Taibi, E.; Bracarda, S.; Porta, C.; Galligioni, E.; Contu, A. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting Future Oncol. 2014, 10.2217/fon.14.48
265. Kim, D.; Lee, M. S.; Jo, K.; Lee, K. E.; Hwang, J. K. Therapeutic potential of panduratin A, LKB1-dependent AMP-activated protein kinase stimulator, with activation of PPARalpha/delta for the treatment of obesity Diabetes Obes. Metab. 2011, 13, 584-593
266. Oh, S.; Kim, S. J.; Hwang, J. H.; Lee, H. Y.; Ryu, M. J.; Park, J.; Jo, Y. S.; Kim, Y. K.; Lee, C. H.; Kweon, K. R.; Shong, M.; Park, S. B. Antidiabetic and antiobesity effects of ampkinone (6f), a novel small molecule activator of AMP-activated protein kinase J. Med. Chem. 2010, 53, 7405-7413
267. Tan, M. J.; Ye, J. M.; Turner, N.; Hohnen-Behrens, C.; Ke, C. Q.; Tang, C. P.; Chen, T.; Weiss, H. C.; Gesing, E. R.; Rowland, A.; James, D. E.; Ye, Y. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway Chem. Biol. 2008, 15, 263-273
268. Chen, X. B.; Zhuang, J. J.; Liu, J. H.; Lei, M.; Ma, L.; Chen, J.; Shen, X.; Hu, L. H. Potential AMPK activators of cucurbitane triterpenoids from Siraitia grosvenorii Swingle Bioorg. Med. Chem. 2011, 19, 5776-5781
269. Meltzer-Mats, E.; Babai-Shani, G.; Pasternak, L.; Uritsky, N.; Getter, T.; Viskind, O.; Eckel, J.; Cerasi, E.; Senderowitz, H.; Sasson, S.; Gruzman, A. Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives J. Med. Chem. 2013, 56, 5335-5350
270. Iwatsuka, H.; Shino, A.; Suzuoki, Z. General survey of diabetic features of yellow KK mice Endocrinol. Jpn. 1970, 17, 23-35
271. Charton, J.; Girault-Mizzi, S.; Debreu-Fontaine, M. A.; Foufelle, F.; Hainault, I.; Bizot-Espiard, J. G.; Caignard, D. H.; Sergheraert, C. Synthesis and biological evaluation of benzimidazole derivatives as potent AMP-activated protein kinase activators Bioorg. Med. Chem. 2006, 14, 4490-4518
272. Pinkosky, S. L.; Filippov, S.; Srivastava, R. A.; Hanselman, J. C.; Bradshaw, C. D.; Hurley, T. R.; Cramer, C. T.; Spahr, M. A.; Brant, A. F.; Houghton, J. L.; Baker, C.; Naples, M.; Adeli, K.; Newton, R. S. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism J. Lipid Res. 2013, 54, 134-151
273. Ballantyne, C. M.; Davidson, M.; MacDougall, D.; Margulies, J.; DiCarlo, L. ETC-1002 lowers LDL-C and beneficially modulates other cardio-metabolic risk factors in hypercholesterolemic subjects with either normal or elevated triglycerides J. Am. Coll. Cardiol. 2012, 59, E1625
274. Chene, P. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface Mol. Cancer Res. 2004, 2, 20-28